News | September 27, 2022
Novartis unveils new focused strategy
Transformation to pure-play Innovative Medicines company nears completion
Transformation to pure-play Innovative Medicines company nears completion
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Based on a post hoc analysis, fewer required respiratory interventions
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
Subscribe To Our Newsletter & Stay Updated
